Cover Image
市場調查報告書

液態切片研究工具、服務、診斷:全球市場

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

出版商 BCC Research 商品編碼 350412
出版日期 內容資訊 英文 282 Pages
訂單完成後即時交付
價格
Back to Top
液態切片研究工具、服務、診斷:全球市場 Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
出版日期: 2017年10月01日 內容資訊: 英文 282 Pages
簡介

全球液態切片 (液態生物檢體) 市場,預計從2017年的15億美元,到2022年擴大到45億美元。預計市場2017年∼2022年以24.2%的年複合成長率成長。

本報告提供全球液態切片研究工具、服務、診斷市場相關調查分析,市場概要,市場趨勢分析與預測,技術的背景,各市場區隔的市場分析,市場動態,主要企業簡介等系統性資訊。

第1章 簡介

第2章 摘要和亮點

第3章 概要

  • 簡介
  • 調查範圍
  • 液態切片 vs. 傳統活體組織切片
  • 市場
  • 成長推動因素
  • 主要趨勢
  • 產業

第4章 技術的背景

  • 液態切片生物標記
  • 癌症基因學
  • 非侵襲產前檢查
  • 循環腫瘤細胞 (CTC) 技術
  • CTC工作流程
  • 細胞離析技術
  • CTC樣品製作技術
  • CTC下游分析技術
  • 液態切片和傳統活體組織切片的比較
    • 癌症檢驗
    • 產前檢查

第5章 液態切片的計劃

第6章 液態切片應用

  • 簡介
  • 癌症應用
  • 生殖健康應用
  • 移植診斷應用

第7章 液態切片產業

  • 簡介
  • NGS設備產業
  • 第3代定序產業
  • 微滴式數位PCR (DDPCR) 產業
  • 靶向序列捕獲、調整產業
  • 單細胞DNA聚合酵素產業
  • 非侵襲產前檢查產業
  • 胎兒細胞NIPT產業
  • CTC採取、檢測產業
  • 液態切片產業
  • D2C遺傳基因檢驗產業

第8章 收購和策略性聯盟

  • 收購
  • 策略性聯盟

第9章 液態切片市場

  • 成長推動因素
  • 液態切片市場:各適應症
  • 液態切片市場:各生物標記類型
  • 液態切片市場:各分析平台
  • 液態切片市場:各分析目的
  • 非侵襲產前檢查市場
  • 癌症市場
  • 移植市場
  • 各地區市場

第10章 專利分析

  • CTC專利
  • 問題點

第11章 企業簡介

關於BCC Research

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO150B

Report Highlights

The global liquid biopsy market should reach $4.5 billion by 2022 from $1.5 billion in 2017 at a compound annual growth rate (CAGR) of 24.2%, from 2017 to 2022.

Report Includes:

  • An overview of the global markets for liquid biopsy research tools, services, and diagnostics
  • Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration
  • Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, and research tools reagents
  • Breakdowns of the market by product, product type, application, end use industry, technology, and indication
  • Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
  • Profiles of major players in the industry

Report Scope

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies.The market sizes for liquid biopsy diagnostics are given for the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy.It then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development.Market driving forces are also discussed.

The structure of several important industry subsectors is reviewed, as well as major industry acquisitions and strategic alliances from January 2016 through July 2017.Industry subsectors analyzed includenext-generation sequencing(NGS) instruments, droplet digital PCR, target enrichment and amplification, single-cell DNA polymerase, prenatal screening, liquid biopsy, direct to consumer, and clinical laboratory.

The market for liquid biopsy diagnostics is analyzed in depth.The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia-Pacific, Rest of World).

Market data cover the years 2015, 2016, 2017 (estimated) and 2022 (forecasted).

More than 165 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2016 through July 2017, including key alliance trends.

Analyst Credentials

John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Overview

  • Introduction
  • Report Scope
  • Liquid Biopsy versus Traditional Biopsy
  • Markets
  • Growth Driving Forces
  • Key Trends
  • Industry

Chapter 4: Technology Background

  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Noninvasive Prenatal Testing
  • Circulating Tumor Cell Technologies
  • CTC Workflow
  • Cell Isolation Technologies
  • CTC Sample Preparation Technologies
  • CTC Downstream Analysis Technologies
  • Comparison of Liquid Biopsy with Conventional Biopsy
    • Cancer Testing
    • Prenatal Testing

Chapter 5: Liquid Biopsy Initiatives

  • Blood Profiling Atlas
  • Cambridge Single Cell Analysis Core Facility
  • Cancer-ID
  • CTCTrap Consortium
  • Early Cancer Detection Consortium
  • Hematologic Oncology Consortium
  • National Center for Single-Cell Biology
  • Precancer Genome Atlas
  • Precision Medicine Initiative
  • Single Cell Analysis Program
  • TopMed
  • Worldwide Innovative Networking (WIN) Consortium

Chapter 6: Liquid Biopsy Applications

  • Introduction
  • Cancer Applications
    • Precision Medicine
    • Cancer Biomarker Status
    • Cancer Market Segments
  • Reproductive Health Applications
  • Transplant Diagnostics Applications

Chapter 7: Liquid Biopsy Industry

  • Introduction
  • NGS Instrument Industry
  • Third-Generation Sequencing Industry
  • Droplet Digital PCR Industry
  • Target Enrichment and Amplification Industry
  • Single-Cell DNA Polymerase Industry
  • NGS Clinical Informatics Industry
  • Testing Services Industry
  • Noninvasive Prenatal Testing Industry
  • Fetal Cell NIPT Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Industry
  • Direct-to-Consumer Genetic Testing Industry

Chapter 8: Acquisitions and Strategic Alliances

  • Acquisitions
  • Strategic Alliances
    • Trends
    • 2016 Alliances
    • 2017 Alliances

Chapter 9: Liquid Biopsy Markets

  • Growth Driving Forces
  • Liquid Biopsy Market by Indication
  • Liquid Biopsy Market by Biomarker Type
  • Liquid Biopsy Market by Analysis Platform
  • Liquid Biopsy Market by Analysis Purpose
  • Noninvasive Prenatal Testing Market
  • Cancer Markets
    • Cancer Market by Indication
    • Cancer Market by Analysis Purpose
    • Cancer Market by Biomarker Class
    • Cancer Market by Analysis Method
    • Breast Cancer Market
    • Colorectal Cancer Market
    • Hematological Cancer Market
    • Lung Cancer Market
    • Pan-Cancer Market
  • Transplant Markets
  • Geographical Market

Chapter 10: Patent Review

  • Circulating Tumor Cell Patents
    • Cell-Free DNA Patents
  • Liquid Biopsy- and Sequencing-Related Patent Issues

Chapter 11: Company Profiles

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2022 ($ Millions)
    • Table 1: Liquid Biopsy Sample Types
    • Table 2: Liquid Biopsy Report Scope
    • Table 3: Global Liquid Biopsy Market, by Analysis Type, Through 2022 ($ Millions)
    • Table 4: Growth Driving Forces
    • Table 5: Key Trends in Liquid Biopsy Market
    • Table 6: Liquid Biopsy Industry Subsectors
    • Table 7: Liquid Biopsy Biomarker Classes
    • Table 8: Single-Cell Analysis to Identify Cancer Driver Mutations
    • Table 9: Genomics-Based Oncology Workflow
    • Table 10: Unique Challenges of CTC Capture and Analysis
    • Table 11: CTC Workflow
    • Table 12: Cell Differentiators
    • Table 13: Cell Isolation Technologies
    • Table 14: CTC Sample Preparation Technologies
    • Table 15: Single-Cell Analysis Technologies
    • Table 16: Estimated Annual Solid Biopsy Procedures Performed in the U.S. for Selected Cancers
    • Table 17: Main Risks for Needle-Based Tissue Biopsies
    • Table 18: Factors in Tissue Biopsy
    • Table 19: Prenatal Invasive Testing Technologies
    • Table 20: Invasive versus Noninvasive Prenatal Technologies
    • Table 21: Key Liquid Biopsy Research and Development Programs
    • Table 22: Source of Foreign Biomarkers for Liquid Biopsy Applications
    • Table 23: Personalized Medicine Driven by Cancer Common Genetic Mutations
    • Table 24: Cancer Liquid Biopsy Biomarker Clinical Status
    • Table 25: Cancer Liquid Biopsy Market Segments
    • Table 26: Reproductive Health Screening Application
    • Table 27: Ethical Issues Associated with NIPT
    • Table 28: Transplant Diagnostics Application
    • Table 29: Key Segments within the Liquid Biopsy Industry
    • Table 30: Next-Generation Sequencing Instrument Companies
    • Table 31: 3GS Industry, by Tier Status
    • Table 32: Advantages of Droplet Digital PCR for Single-Cell Analysis
    • Table 33: Droplet Digital PCR Industry
    • Table 34: Target Enrichment Industry
    • Table 35: Single-Cell DNA Polymerase Industry
    • Table 36: Next-Generation Sequencing Clinical Informatics Company Positioning
    • Table 37: Selected NGS Clinical Testing Laboratories
    • Table 38: NIPT Industry
    • Table 39: Global Market Share for NIPT, by Company and by Region, 2017
    • Table 40: German NGS-based Noninvasive Prenatal Diagnostic Companies, 2017
    • Table 41: NIPT Test Licensing, by Country
    • Table 42: Fetal Cell NIPT Industry
    • Table 43: CTC Capture and Detection Industry
    • Table 44: Liquid Biopsy Industry Company Focus
    • Table 45: Example of NGS-based Liquid Biopsy Market Differentiation
    • Table 46: Key Competitors in the Direct-to-Consumer Genetic Testing Industry
    • Table 47: Liquid Biopsy Industry Acquisitions, January 2016-July 2017
    • Table 48: Liquid Biopsy Strategic Alliances, January 2016-July 2017
    • Table 49: Liquid Biopsy Key Growth Driving Forces
    • Table 50: Global Liquid Biopsy Market, by Indication, Through 2022 ($ Millions)
    • Table 51: Global Liquid Biopsy Market, by Biomarker Type, Through 2022 ($ Millions)
    • Table 52: Global Liquid Biopsy Market, by Analysis Platform, Through 2022 ($ Millions)
    • Table 53: Global Liquid Biopsy Market, by Analysis Purpose, Through 2022 ($ Millions)
    • Table 54: Global NIPT Market, by Analysis Purpose, Through 2022 ($ Millions)
    • Table 55: Global NIPT Market, by Risk Type, Through 2022 ($ Millions)
    • Table 56: Global NIPT Market, by Biomarker Class, Through 2022 ($ Millions)
    • Table 57: Global NIPT Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 58: Limitations of Solid Biopsy in Cancer Applications
    • Table 59: Global Cancer Market, by Indication, Through 2022 ($ Millions)
    • Table 60: Five-Year Survival Rate for Ovarian Cancer (%)
    • Table 61: Prostate Cancer Testing Industry
    • Table 62: Molecular Thyroid Nodule Classifier Test Company Positioning
    • Table 63: Global Cancer Market, by Analysis Purpose, Through 2022 ($ Millions)
    • Table 64: Cancer Detection Methods
    • Table 65: Early Detection Tissue of Origin Approaches
    • Table 66: NGS Instrument Company Companion Diagnostics Status
    • Table 67: Global Cancer Market, by Biomarker Class, Through 2022 ($ Millions)
    • Table 68: Global Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 69: Global Breast Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 70: Global Colorectal Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 71: Global Hematological Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 72: Global Lung Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 73: Global Pan-Cancer Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 74: Global Liquid Biopsy Transplant Market, by Analysis Purpose, Through 2022 ($ Millions)
    • Table 75: Global Liquid Biopsy Transplant Market, by Organ Type, Through 2022 ($ Millions)
    • Table 76: Transplant Procedures Performed in the U.S., 2015 and 2016
    • Table 77: Global Liquid Biopsy Transplant Market, by Analysis Method, Through 2022 ($ Millions)
    • Table 78: Global Liquid Biopsy Transplant Market, by Biomarker Class, Through 2022 ($ Millions)
    • Table 79: Global Liquid Biopsy Market, by Region, Through 2022 ($ Millions)
    • Table 80: Global Cancer Liquid Biopsy Market, by Region, Through 2022 ($ Millions)
    • Table 81: Global NIPT Market, by Region, Through 2022 ($ Millions)
    • Table 82: Global Transplant Market, by Region, Through 2022 ($ Millions)
    • Table 83: CTC-Related Patents, by Region, 2007-2017
    • Table 84: Cell-Free DNA-Related Patents, by Region, 2007-2017
    • Table 85: Status of Liquid Biopsy and Sequencing-Related Patent Disputes
    • Table 86: Sensitivity to Detect Drug-resistant Mutations in Viruses (%)

List of Figures

  • Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2015-2022 ($ Millions)
    • Figure 1: How Cancer Genomics Drives Liquid Biopsy
Back to Top